Kosei Yasumoto
Overview
Explore the profile of Kosei Yasumoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
144
Citations
2155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Takimoto R, Kamigaki T, Ito H, Saito M, Takizawa K, Soejima K, et al.
Cytotherapy
. 2023 Jul;
25(11):1229-1235.
PMID: 37486281
Background Aims: With the aim of strengthening the scientific evidence of immune-cell therapy for cancer and further examining its safety, in October 2015, our hospital jointly established the Cancer Immune-Cell...
2.
Ichiki Y, Shigematsu Y, Baba T, Shiota H, Fukuyama T, Nagata Y, et al.
Cancer Sci
. 2020 Aug;
111(11):4021-4030.
PMID: 32780528
The present study analyzed the antitumor effect of γδT cells transduced with the TCR of cancer-specific CTLs to establish forceful cancer-specific adoptive immunotherapy. We cloned the TCRαβ genes from CTLs...
3.
Yamada T, Yoshida Y, Maeda T, Yoshimatsu G, Aisu N, Yamashita K, et al.
Anticancer Res
. 2020 Jul;
40(8):4763-4771.
PMID: 32727803
Background/aim: Chemoimmunotherapy is a promising treatment for various malignant diseases. In this study, we examined whether first-line chemoimmunotherapy using adoptive immune-cell therapy was effective for metastatic colorectal cancer (mCRC). Patients...
4.
Goto S, Terao Y, Kamigaki T, Takimoto R, Naitoh K, Makita K, et al.
Anticancer Res
. 2020 Jul;
40(8):4741-4748.
PMID: 32727800
Background/aim: We aimed to investigate the efficacy of immune-cell therapy in terms of the survival of patients with neuroendocrine carcinoma of the uterine cervix (NECC), which lacks standardized therapeutic approaches....
5.
Takimoto R, Kamigaki T, Okada S, Ibe H, Oguma E, Naitoh K, et al.
Anticancer Res
. 2020 Jul;
40(8):4729-4740.
PMID: 32727799
Background/aim: In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy using T lymphocytes activated in vitro with or without dendritic cell vaccination in combination with standard...
6.
Takimoto R, Miyashita T, Mizukoshi E, Kamigaki T, Okada S, Ibe H, et al.
Cytotherapy
. 2020 Apr;
22(6):329-336.
PMID: 32303429
Background Aims: Activated γδT cells have been shown to exhibit cytotoxicity against tumor cells. However, the efficacy of γδT cell immunotherapy for a large number of patients with solid tumors...
7.
Expression of KK-LC-1, a cancer/testis antigen, at non-tumour sites of the stomach carrying a tumour
Fukuyama T, Futawatari N, Yamamura R, Yamazaki T, Ichiki Y, Ema A, et al.
Sci Rep
. 2018 Apr;
8(1):6131.
PMID: 29666402
Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) and predominant target for cancer immunotherapy. Our previous study indicated that KK-LC-1 was expressed in 82% of gastric cancers, and...
8.
Yoshida Y, Naito M, Yamada T, Aisu N, Kojima D, Mera T, et al.
Anticancer Res
. 2017 Jul;
37(7):3941-3946.
PMID: 28668898
Background: Adoptive immunotherapy for cancer has evolved through development of novel technologies for generating a large number of activated killer cells, such as αβ T-cells, γδ T-cells, and natural killer...
9.
Ishii F, Yoshida Y, Yamauchi Y, Aisu N, Kojima D, Mera T, et al.
Anticancer Res
. 2017 Jul;
37(7):3933-3939.
PMID: 28668897
Background/aim: Various types of chemoimmunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients...
10.
Yoshida Y, Naito M, Yamada T, Aisu N, Daibo K, Mera T, et al.
Anticancer Res
. 2016 Jun;
36(7):3741-6.
PMID: 27354648
Background/aim: Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of αβ and γδ T cells. We evaluated the safety and...